Oct 24, 2019

Amgen Named 2019 Foreign Company of the Year

Amgen is recognized for their valuable investments in Danish innovation, research, and development within biotechnology.

An independent jury has selected Amgen as the AmCham’s 2019 Foreign Company of the Year. The jury placed emphasis on the growth of the company’s Danish activities along with the valuable investments made in Denmark focusing on research.

Spokesperson for the Jury, Jørgen Bardenfleth, Chairman (Lyngsoe Systems, Symbion et al.), says: “With the acquisition of first Novo Nordisk Device Engineering, and now also Nuevolution, Amgen demonstrates a strong conviction in the capabilities of the Danish biotechnology sector and a commitment to make innovation available for patients and society in Denmark in the future. Furthermore, by committing to a strong collaboration with Danish public institutions such as University of Aarhus, Amgen has built a strong foundation for global knowledge sharing on real-world use of Amgen treatments.”

The 2019 jury was comprised of Jørgen Bardenfleth, Thomas Bustrup, COO at DI and Sanna Suvanto-Haarsae, Chairman (Bo Concept, TCM, etc.).

Tore von Würden, Country Director, Amgen, says: “We are honored to receive the prestigious ´2019 Foreign Company of the Year’ award. Having invested more than 1.3B DKK in Danish innovation, research, and development, Denmark is now a key pillar in Amgen’s core strategy to address the challenges we see in biotech. This award is a great recognition of Amgen’s highly exciting ongoing journey in Denmark.”

He continues: “Denmark is a great place for Amgen to expand our business because of the easy access to the local biotech network and a highly talented, technically savvy workforce. As the market for innovative medicine and new patient solutions keep growing, we expect to continue investing in our Denmark presence.”

AmCham Denmark is proud to recognize Amgen as the 2019 Foreign Company of the Year. “This award recognizes the importance and positive impact made by foreign companies investing in Denmark – which comprise only 1.2% of private sector companies but create more than 20% of the private sector jobs,” says Stephen Brugger, AmCham Executive Director.

Foreign companies hold the key to future growth in the economy, and when they choose to invest in Denmark, it creates jobs, growth and innovation. Therefore, it is a privilege for AmCham to help foreign companies tell their success stories – and this year’s finalists were five multinational companies from the absolute top drawer, who provided the jury with several great stories to choose from,” adds Brugger.

AmCham would like to congratulate this year’s other finalists: Bayer, Dell, MSD and Philips – who were all very qualified and made the jury’s decision extremely difficult. Read about the finalists here.

Amgen joins a prestigious list of previous award winners including: FMC (2018), Medtronic (2017), Dupont (2016), Bayer (2015), Roche (2014), Biogen Idec (2013), McDonald’s (2012), Siemens (2011), Crowne Plaza Copenhagen Towers (2010), Iron Mountain (2009) and GlaxoSmithKline (2008).